about
Histidine-rich glycoprotein uptake and turnover is mediated by mononuclear phagocytesInfluence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterpartsIn vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imagingEvaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody.Update: affibody molecules for molecular imaging and therapy for cancer.The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule.(99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversificationTargeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expressionThe effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin.Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides.Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of RadioactivityADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers.Affibody-mediated PET imaging of HER3 expression in malignant tumours.Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant TumorsMeasuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules.Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody moleculesFeasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator.Synthesis of 11C-labeled Sulfonyl Carbamates through a Multicomponent Reaction Employing Sulfonyl Azides, Alcohols, and [11C]CO.In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct.Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets.Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls.Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine.Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6.Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin.Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX.Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting.Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors.The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re.188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment.Position for site-specific attachment of a DOTA chelator to synthetic affibody molecules has a different influence on the targeting properties of 68Ga- compared to 111in-labeled conjugates.In vitro modeling of HER2-targeting therapy in disseminated prostate cancer.Gallium-68-labeled affibody molecule for PET imaging of PDGFRβ expression in vivo.Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution.Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule.
P50
Q27347296-B63B3F6E-3ABF-4E54-90E4-890F4203D0D4Q28535054-EB1E1A52-312A-4B77-9465-08F024416F27Q28535729-3E10D8BA-5EE4-41AA-89BE-A3761CBE59BDQ33227175-E9FD964F-6283-468D-9EF7-2D33892D192BQ33304850-E9632127-ECF0-4FA0-BE2F-31FCDC356A98Q33920975-DCF05344-3E05-4E25-84B3-FBFFD1DB788DQ34703098-7B382BA4-A4CC-497C-9FA8-A44D1666EBB7Q34722687-60D90290-4880-4046-B2F3-21085DE3D270Q34976211-55F8FA9D-16EB-4E41-A14D-900D6C099A51Q34996772-1DD76CC8-8B17-4826-AC2D-A4EF2F2132D8Q35208747-09F74428-63C6-4B94-8E1F-F650D6C8FBBEQ35552126-C2705D9A-C18B-4C93-9426-206F2BDA9676Q35571891-9E37F640-76FA-46BF-9C41-5166DAB2D928Q35752923-674CA6C1-8CE0-4DED-9330-944D6CDB2681Q36174716-C475F4B5-5385-4C89-8A33-648F9CD4212AQ36372344-5FD38C3A-0259-45CC-99E7-CEB9ECA10800Q36510875-4548071D-E0FB-4136-8B8B-1506D48F29DFQ36649532-56C5C659-4EF1-4A3A-A52F-03570080A4C4Q36922818-E88ECB34-A03E-480D-8273-FB29DEF32BC0Q37427038-25DF5C83-2503-47E6-9881-8F73D7913C1CQ37515306-FF1D92D5-02EA-4926-9341-2E1BE4970CD6Q37660979-230F47C7-0521-4AE2-BC98-BE2D9876CB0AQ37758861-35C86641-22F9-4796-8A0C-BB217835069BQ37776361-BA39F7E5-FFED-4F88-9A7C-C03D2BFC896FQ38136357-1342EE44-8B2C-4A7B-8A5E-86F146E6E726Q38741232-E5EA2B9C-57F0-4280-A284-D2434D89CF9DQ38749222-15A105FF-9C29-4334-98B4-6DD1D2218E9AQ38751583-786A8214-0564-4D92-958B-2743787EF31BQ38785819-836D6870-99B4-4F12-8684-95EEC7D35811Q38812258-8A0819DE-07D0-4BB4-9659-C79755E01646Q38865622-41236409-8A9A-4AB2-A4BC-6D04E47221E3Q38909220-062BB8D3-1424-45D0-93CD-F4BE266F6F09Q38950538-FAB8E68E-7C5A-416D-B251-EA874FE33FC8Q38950904-ABE493F5-04E0-45CF-8889-FFFD9A37D818Q38953910-06515DD0-FFF8-4B0B-A188-8ABF8CF2F080Q38961024-285D4B25-8B80-4A13-B114-53FB9A3A04AFQ38980385-0F3B389F-AED4-434A-9D82-DB35ADE522D7Q39000510-676C96B8-BF8C-4A9D-B713-228683A80F5BQ39005734-EBB576A2-F090-478E-850A-1CC4CB083020Q39016180-ED848C90-C858-49F2-BA29-6B191AE9E82A
P50
description
researcher
@en
wetenschapper
@nl
name
Anna Orlova
@en
Orlova A
@nl
type
label
Anna Orlova
@en
Orlova A
@nl
altLabel
Orlova A
@en
prefLabel
Anna Orlova
@en
Orlova A
@nl
P106
P31
P496
0000-0001-6120-2683